盐酸硫乙胺(Cysteamine Hydrochloride) - 药物靶点：GSS_在研适应症：胱氨酸贮积症，胃肠道间质瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

mercaptamine、mercaptamine hydrochloride、CI-9148

+ [8]

靶点

GSS

作用机制

GSS刺激剂(谷胱甘肽合成酶刺激剂)

治疗领域

肿瘤遗传病与畸形消化系统疾病+ [3]

在研适应症

胱氨酸贮积症胃肠道间质瘤

非在研适应症

角膜疾病

原研机构

Leadiant Biosciences, Inc.

在研机构

Recordati Rare Diseases, Inc.

Recordati Rare Diseases

Leadiant Biosciences, Inc.

+ [1]

非在研机构

Lucane Pharma SA

最高研发阶段批准上市

首次获批日期

美国 (2012-10-02),

胱氨酸贮积症胃肠道间质瘤

最高研发阶段(中国)-

特殊审评孤儿药 (欧盟)、孤儿药 (澳大利亚)、孤儿药 (美国)

登录后查看时间轴

结构

分子式C2H8ClNS

InChIKeyOGMADIBCHLQMIP-UHFFFAOYSA-N

CAS号156-57-0

关联

4

项与盐酸硫乙胺相关的临床试验

NCT04125927 / Completed临床3期

Open-label, Single-arm, Multicenter Study to Assess the Safety of Cystadrops® in Pediatric Cystinosis Patients From 6 Months to Less Than 2 Years Old

Cystadrops® is currently indicated in adults and children from 2 years of age diagnosed with cystinosis with corneal crystal accumulation observed.
However administration of Cystadrops® in patients below 2 years old could be of value for these patients and prevent the crystal deposit. It is the reason why as part of the Cystadrops® pediatric investigational plan (PIP), RECORDATI Rare Diseases committed to conduct a clinical study to assess Cystadrops® safety and efficacy in the pediatric population from 6 months to less than 2 years old.

开始日期2020-09-01

申办/合作机构

Recordati Rare Diseases

EUCTR2009-012564-13-FR / Not yet recruitingN/A

Cysteamine Hydrochloride for nephropathic Cystinosis, open-label Phase III pivotal study - CYSTADROPS CHOC study

开始日期2013-01-03

申办/合作机构

Orphan Europe SARL

EUCTR2007-006024-35-FR / Not yet recruitingN/A

Adaptive dose regimen of Cystadrops for cOrneal Crystal deposiTs and ocular manifestations in nephropathic cystinosis : an open label, dose-response pilot study - CYSTADROPS OCT-1 pilot study

开始日期2008-02-04

申办/合作机构

Orphan Europe SARL

100 项与盐酸硫乙胺相关的临床结果

登录后查看更多信息

100 项与盐酸硫乙胺相关的转化医学

登录后查看更多信息

100 项与盐酸硫乙胺相关的专利（医药）

登录后查看更多信息

122

项与盐酸硫乙胺相关的文献（医药）

2025-02-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Silver nanoparticles modified with MoS2 and β-cyclodextrin as SERS substrate for rapid determination of cysteamine hydrochloride in meat products

Article

作者: Yang, Bin ; Wang, Yuting ; Liu, Xin ; Niu, Shiyue ; Zhang, Fengming ; Liu, Jia ; Bi, Shuyun

An efficient Surface-enhanced Raman scattering (SERS) method for the detection of cysteamine hydrochloride (CSH) was developed by synthesizing a composite substrate comprising silver nanoparticles (AgNPs) functionalized with MoS₂ and β-cyclodextrin (β-CD). The enhanced Raman signals of CSH by β-CD/MoS₂/AgNPs substrate were the contribution of electromagnetic enhancement (EM) as well as chemical enhancement (CM), and the enhancement factor (EF) can reach up to 3.11 × 10⁶ (peak at 633 cm^-1). Various instrumental techniques were used to characterize the substrate, such as X-ray diffraction (XRD), thermogravimetric analysis (TGA), transmission electron microscopy (TEM), high-angle annular dark field scanning transmission electron microscopy (HAADF-STEM) and ultraviolet visible (UV-vis). The binding of β-CD/MoS₂/AgNPs and CSH was confirmed by UV-vis and Fourier transform infrared (FT-IR). The optimal experimental conditions were determined by single factor experiments as well as response surface model. The influences of different metal ions and analogous drugs on the detection of CSH were investigated. Under optimum conditions, a good linear correlation (R = 0.9997) was established for CSH in the range of 10.00-1000.00 nmol/L, and the limit of detection (LOD) was as low as 0.78 nmol/L (S/N = 3). The contents of CSH in meat samples were detected. The recovery was 96.6-103.1 %, and the relative standard deviation (RSD) of the measurement was 0.7-3.9 % (n = 7).

2024-11-05·LANGMUIR

Adsorption of l-Cysteine and Cysteamine on Zinc Oxide Nanoparticles

Article

作者: Cozzens, Yuqing ; Wang, Peng ; Whitten, James E.

The reaction of l-cysteine and cysteamine hydrochloride with zinc oxide nanoparticles (ZnO NPs), by stirring excess reactant with the NPs in ethanol, has been studied by thermal gravimetric analysis (TGA), transmission electron microscopy (TEM), X-ray photoelectron spectroscopy (XPS), X-ray diffraction (XRD), and Raman spectroscopy. l-Cysteine adsorption occurs via the thiol functional group, and there is no evidence for bonding via the carboxylic acid or amine functionalities. However, Raman spectroscopy and XPS reveal some protonated thiol, suggesting unbound l-cysteine is also present, as confirmed by XRD that shows the presence of l-cysteine crystallites. In the case of cysteamine/ZnO, TGA indicates that a large fraction of the sample is organic, and Raman spectroscopy reveals a dramatic shift in the C-S stretch from 796 cm^-1 for unreacted cysteamine to 837 cm^-1 for the reacted cysteamine. It is postulated that the acidic and chelating nature of the reaction causes dissolution of some Zn²⁺ ions that form a Zn(II) coordination complex with cysteamine. These studies have implications for biomolecular applications in which ZnO nanoparticles are used for biosensors, bioimaging, and drug delivery.

2024-01-01·ANIMAL SCIENCE JOURNAL

Effects of various levels of coated cysteamine hydrochloride in the diet on feed intake, digestibility, ruminal fermentation, and blood metabolites in growing Charolais crossbred cattle

Article

作者: Waramit, Naroon ; Siriket, Chakkrit ; Modak, Tanmay ; Meenongyai, Watcharawit ; Kabir, A. K. M. Ahsan ; Wongpanit, Kannika ; Rahman, Md Abdur ; Kokaew, Nattawut ; Kamkuan, Pramoet ; Manabe, Noboru ; Papsaree, Sahapap ; Khamngamdi, Phongphet ; Tammanoi, Chayanun ; Srijan, Artsani ; Phungkrathok, Natthaphon ; Siam, Md Sifat Habib ; Khejornsart, Pichad ; Phongkaew, Piyamas ; Namwongsa, Nuttawut

Abstract:

This study investigated the impact of different levels of coated cysteamine hydrochloride (CSH) supplementation on ruminal fermentation, nutrient digestibility, and blood metabolites in Charolais cross bulls. Twelve bulls were allotted to three feeding treatments in a replicated 3 × 3 Latin square design: 0% CSH (control), 0.5% CSH, and 1.0% CSH in concentrate. Animals were fed concentrate at 1.5% of body weight. Dry matter intake (DMI) and DMI as a percentage of body weight showed no significant differences among treatments (p > 0.10). Nutrient digestibility was consistent across treatments, except for a slight decrease in NDF digestibility with 1% CSH (p = 0.07). Ruminal pH, ammonia nitrogen, volatile fatty acid (VFA) proportions, and total VFA concentration were similar among treatments (p > 0.05). Total bacteria, fungal zoospores, and protozoa populations in the rumen did not vary significantly (p > 0.05). Blood glucose and triglyceride concentrations remained stable (p > 0.05), while blood urea nitrogen (BUN) levels were higher in CSH‐supplemented groups (p < 0.05). In conclusion, incorporating CSH levels ranging from 0.5% to 1.0% into the diet did not adversely affect feed intake, ruminal fermentation, or microbial populations. Additionally, 1.0% CSH improved BUN concentration in growing Charolais cross bulls.

100 项与盐酸硫乙胺相关的药物交易

登录后查看更多信息